Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amcinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | PGR | P06401 | 5/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | AR | P10275 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amcinonide SCHEMBL13026154 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL21051752 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL4720 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL5488922 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| Amcinonide SCHEMBL12396698 | 1.00 | HIF1A (1.00) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL11422147 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL15975096 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL28971361 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL14884636 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR | |
| SCHEMBL124165 | 0.93 | HIF1A (0.87) | HIF1ALMNACYP3A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036241-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3025714-B9 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200325543-A1 | DIAGNOSTIC METHOD | TOLREMO THERAPEUTICS AG (CH) | 2020-10-15 | — | — | US | disclosed |
| EP-3025714-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200179451-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | JUNO THERAPEUTICS, INC. | 2020-06-11 | — | — | US | disclosed |
| US-20160151390-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN MA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-3025714-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9233107-B2 | Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML) | BIOGEN MA INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20130183289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | BIOGEN IDEC MA INC (US) | 2013-07-18 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |